<DOC>
	<DOCNO>NCT02770729</DOCNO>
	<brief_summary>There thus far one randomize mask clinical trial world evaluate efficacy intraoperative intracameral injection antibiotic objective prevent endophthalmitis follow cataract surgery . The ESCRS study 2007 confirm intracameral use cefuroxime reduce incidence endophthalmitis approximately fivefold . Unlike Europe , drug come widely use 2007 result , cefuroxime commercially available Brazil . Many study around world substitute cefuroxime moxifloxacin , drug easily find around world eye drop form . It widely use postoperative regimen case ophthalmologic surgery , free preservative toxic intraocular structure ( corneal endothelial cell ) . Three study ( respective ) find intracameral use moxifloxacin safe effective prevent endophthalmitis follow cataract surgery ; however , control , randomize , mask clinical trial perform objective . If trial confirms hypothesis ( reduction incidence endophthalmitis follow cataract surgery ) minimal side effect report , moxifloxacin may option routine intracameral use cataract surgery , thus reduce case endophthalmitis consequent case blindness .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Intracameral Moxifloxacin Prevention Postcataract Endophthalmitis .</brief_title>
	<detailed_description>Patients diagnose cataract surgery indicate shall evaluate term visual acuity refractive error via biomicroscopy , automate keratometry ( Auto Kerato Refractometer KR 8000® Alcon ) , Goldmann applanation tonometry , fundoscopy , biometric assessment ( Ocuscan RxP® Alcon Lenstar LS900® Haag-Streit International ) , specular microscopy cornea ( EM-3000® Tomey ) count corneal endothelial cell . Each cataract case shall classify base Lens Opacities Classification System III ( LOCS III ) . Patients choose sign inform consent form inform aspect surgery trial shall randomly divide 2 group shall approximately equal size stratify gender . Group A shall receive intracameral injection 0.03ml 0.5 % moxifloxacin ( 150 microgram 0.03 ml ) end cataract surgery , follow use 0.5 % moxifloxacin eye drop form associate 0.1 % dexamethasone bandage apply . Group B shall receive intracameral moxifloxacin injection end cataract surgery ; patient shall receive 0.5 % moxifloxacin eye drop form associate 0.1 % dexamethasone bandage apply . The cataract surgery shall perform use standard follow Department Ophthalmology São Paulo State University , Campinas ( UNICAMP ) . It shall perform second- , third- , fourth-year ophthalmology resident attendings case complex . Preoperative pupil dilation shall perform use 10 % phenylephrine 1 % tropicamide 3 time five-minute increment . The anesthesiology technique use shall depend case shall either topical anesthesia , peribulbar anesthesia , sub-Tenon anesthesia , general anesthesia . Skin sterilization shall perform use aqueous solution 10 % povidone-iodine . After sterile surgical field establish eyelashes isolate , 4 eye drop contain 5 % povidone-iodine shall administer conjunctival sac subsequent irrigation use 10 % balanced salt solution . In case allergy povidone-iodine , aqueous solution 0.05 % chlorhexidine shall use . The principal incision ( use clear corneal incision near clear approach ) shall 2.2mm 3.0mm length . The phacoemulsification technique shall either stop chop , phaco chop , pre-slice , pre-chop , divide conquer ; shall apply use Infiniti® Laureate® phacoemulsifier ( Alcon ) , AcrySof® intraocular foldable lens ( Alcon ) . In case posterior capsule rupture vitreous loss , complication increase chance endophthalmitis,3,4,15 mechanical manual anterior vitrectomy shall perform ( choice shall depend case ) . In case thermal burn principal incision situation surgical injury self-sealing consequent leak aqueous humor inability keep anterior chamber adequate dimension , incision shall suture use Mononylon 10.0 . The moxifloxacin injection shall prepare trained nurse physician : 0.03ml ( 150 microgram ) 0.5 % moxifloxacin ophthalmic solution ( Vigamox® ) shall aspirate . The eye drop bottle shall open moment preparation 0.3ml couple syringe ( Terumo® ) use asseptic technique . The solution shall inject anterior chamber via paracentesis last step phacoemulsification surgery . The patient two group shall receive 0.5 % moxifloxacin drop associate 0.1 % dexamethasone surgery complete bandage apply . The postoperative prescription shall consist 0.5 % moxifloxacin associate 0.1 % dexamethasone . Administration shall begin 3 hour surgery complete continue every 3 hour 7 day ( except patient sleep ) . After 7th postoperative day , 0.1 % dexamethasone without association moxifloxacin shall prescribe . Its application shall gradually reduce course 3 week accord individual 's inflammatory response . Patients group shall mask , surgeon ophthalmologist perform postoperative examination . In suspected case endophthalmitis , independent ophthalmologist retina vitreous practice shall perform patient 's examination without know whether patient belongs Group A Group B . This independent ophthalmologist shall recommend adequate course action . Endophthalmitis treatment shall follow usual protocol . The postoperative consults shall hold 1st , 7th , 30th , 60th postoperative day shall include evaluation visual acuity ( 7th , 30th , 60th postoperative day ) , refractive error ( 30th postoperative day ) , biomicroscopy ( 1st , 7th , 30th , 60th postoperative day ) , applanation tonometry ( 7th , 30th , 60th postoperative day ) , keratometry ( 30th postoperative day ) , fundoscopy ( 30th , 60th post operative day ) , endothelial cell count ( 60th postoperative day ) .</detailed_description>
	<mesh_term>Endophthalmitis</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Diagnosis visually significant cataract Exclusion Criteria Vulnerable group Moxifloxacin allergy Traumatic cataract ocular perforation Cataract surgery associate procedure , glaucoma filtering surgery , vitreoretinal surgery , cornea surgery Signs ocular periocular infection Advanced glaucoma Severe dry eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>intracameral moxifloxacin</keyword>
	<keyword>endophthalmitis</keyword>
	<keyword>Vigamox</keyword>
	<keyword>endothelial cell density</keyword>
</DOC>